Key points are not available for this paper at this time.
Abstract Background Tumor Treating Fields (TTFields) are alternating electric fields that disrupt cancer cell processes. TTFields therapy is approved for recurrent glioblastoma (rGBM), and newly-diagnosed (nd) GBM (with concomitant temozolomide for ndGBM; US), and for grade IV glioma (EU). We present an updated global, post-marketing surveillance safety analysis of patients with CNS malignancies treated with TTFields therapy. Methods Safety data were collected from routine post-marketing activities for patients in North America, Europe, Israel, and Japan (October 2011–October 2022). Adverse events (AEs) were stratified by age, sex, and diagnosis. Results Overall, 25,898 patients were included (diagnoses: ndGBM 68%, rGBM 26%, anaplastic astrocytoma/oligodendroglioma 4%, other CNS malignancies 2%). Median (range) age was 59 (3–103) years; 66% patients were male. Most (69%) patients were 18–65 years; 0.4% were 65 years. All-cause and TTFields-related AEs occurred in 18,798 (73%) and 14,599 (56%) patients, respectively. Most common treatment-related AEs were beneath-array skin reactions (43%), electric sensation (tingling; 14%), and heat sensation (warmth; 12%). Treatment-related skin reactions were comparable in pediatric (39%), adult (42%), and elderly (45%) groups, and in males (41%) and females (46%); and similar across diagnostic subgroups (ndGBM, 46%; rGBM, 34%; anaplastic astrocytoma/oligodendroglioma, 42%; other, 40%). No TTFields-related systemic AEs were reported. Conclusions This long-term, real-world analysis of > 25,000 patients demonstrated good tolerability of TTFields in patients with CNS malignancies. Most therapy-related AEs were manageable localized, non-serious skin events. The TTFields therapy safety profile remained consistent across subgroups (age, sex, and diagnosis), indicative of its broad applicability.
Mrugała et al. (Sat,) studied this question.